Karyopharm Therapeutics Inc. (KPTI) Shares Sold by Wells Fargo & Company MN

Wells Fargo & Company MN lessened its position in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) by 46.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 23,552 shares of the company’s stock after selling 20,054 shares during the quarter. Wells Fargo & Company MN’s holdings in Karyopharm Therapeutics were worth $213,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. American International Group Inc. raised its holdings in shares of Karyopharm Therapeutics by 20.9% in the 1st quarter. American International Group Inc. now owns 16,422 shares of the company’s stock valued at $211,000 after buying an additional 2,836 shares during the period. Trexquant Investment LP purchased a new stake in shares of Karyopharm Therapeutics in the 2nd quarter valued at $202,000. State of Wisconsin Investment Board purchased a new stake in Karyopharm Therapeutics during the 2nd quarter worth about $235,000. Parametric Portfolio Associates LLC increased its holdings in Karyopharm Therapeutics by 38.6% during the 1st quarter. Parametric Portfolio Associates LLC now owns 27,988 shares of the company’s stock worth $359,000 after purchasing an additional 7,789 shares during the period. Finally, Bank of America Corp DE increased its holdings in Karyopharm Therapeutics by 0.7% during the 1st quarter. Bank of America Corp DE now owns 46,127 shares of the company’s stock worth $592,000 after purchasing an additional 308 shares during the period. Hedge funds and other institutional investors own 59.52% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The legal version of this news story can be viewed at https://sportsperspectives.com/2017/11/22/karyopharm-therapeutics-inc-kpti-shares-sold-by-wells-fargo-company-mn.html.

In related news, Director Mansoor Raza Mirza sold 2,882 shares of the company’s stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $11.00, for a total value of $31,702.00. Following the completion of the sale, the director now directly owns 2,882 shares of the company’s stock, valued at approximately $31,702. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Christopher Brett Primiano sold 4,958 shares of the company’s stock in a transaction dated Tuesday, November 7th. The shares were sold at an average price of $11.25, for a total value of $55,777.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 15,653 shares of company stock worth $174,728. Company insiders own 14.71% of the company’s stock.

Several equities research analysts have weighed in on the company. assumed coverage on Karyopharm Therapeutics in a report on Wednesday, November 15th. They set a “buy” rating and a $23.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $23.00 price target on shares of Karyopharm Therapeutics in a report on Wednesday, November 15th. Zacks Investment Research downgraded Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, November 7th. Royal Bank Of Canada restated a “buy” rating and set a $15.00 price target on shares of Karyopharm Therapeutics in a report on Friday, November 3rd. Finally, Robert W. Baird restated a “buy” rating on shares of Karyopharm Therapeutics in a report on Friday, November 3rd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $17.33.

Karyopharm Therapeutics Inc. (NASDAQ KPTI) opened at $11.07 on Wednesday. Karyopharm Therapeutics Inc. has a 1-year low of $7.48 and a 1-year high of $14.63.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings data on Thursday, November 2nd. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 76.83%. sell-side analysts forecast that Karyopharm Therapeutics Inc. will post -2.59 EPS for the current fiscal year.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Want to see what other hedge funds are holding KPTI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Karyopharm Therapeutics Inc. (NASDAQ:KPTI).

Institutional Ownership by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply